Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.

•This study assessed durvalumab in patients with R/M HNSCC and PD-L1-high expression.•Patients had failed 1 platinum-based chemotherapeutic regimen in the R/M setting.•The ORR for all patients was 16.2% with a median OS of 7.1 months.•HPV-positive patients had a numerically higher response rate and longer survival.•Durvalumab showed antitumour activity with acceptable safety in the HAWK study.